Endonovo Therapeutics Stock Net Income
| ENDV Stock | USD 0.0001 0.00 0.00% |
As of the 5th of February, Endonovo Therapeutics shows the Standard Deviation of 6.15, mean deviation of 1.49, and Coefficient Of Variation of (812.40). Endonovo Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Endonovo Therapeutics market risk adjusted performance and total risk alpha to decide if Endonovo Therapeutics is priced favorably, providing market reflects its regular price of 1.0E-4 per share. As Endonovo Therapeutics appears to be a penny stock we also advise to verify its information ratio numbers.
Endonovo Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Endonovo Therapeutics' valuation are provided below:Endonovo Therapeutics does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Endonovo |
Endonovo Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Endonovo Therapeutics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Endonovo Therapeutics.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Endonovo Therapeutics on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Endonovo Therapeutics or generate 0.0% return on investment in Endonovo Therapeutics over 90 days. Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutic... More
Endonovo Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Endonovo Therapeutics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Endonovo Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 50.0 |
Endonovo Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Endonovo Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Endonovo Therapeutics' standard deviation. In reality, there are many statistical measures that can use Endonovo Therapeutics historical prices to predict the future Endonovo Therapeutics' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.77) | |||
| Total Risk Alpha | (1.22) | |||
| Treynor Ratio | 25.42 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Endonovo Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Endonovo Therapeutics February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | 25.43 | |||
| Mean Deviation | 1.49 | |||
| Coefficient Of Variation | (812.40) | |||
| Standard Deviation | 6.15 | |||
| Variance | 37.88 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.77) | |||
| Total Risk Alpha | (1.22) | |||
| Treynor Ratio | 25.42 | |||
| Maximum Drawdown | 50.0 | |||
| Skewness | (8.12) | |||
| Kurtosis | 66.0 |
Endonovo Therapeutics Backtested Returns
Endonovo Therapeutics is out of control given 3 months investment horizon. Endonovo Therapeutics secures Sharpe Ratio (or Efficiency) of 0.11, which denotes the company had a 0.11 % return per unit of standard deviation over the last 3 months. We were able to break down nineteen different technical indicators, which can help you to evaluate if expected returns of 14.75% are justified by taking the suggested risk. Use Endonovo Therapeutics Coefficient Of Variation of (812.40), mean deviation of 1.49, and Standard Deviation of 6.15 to evaluate company specific risk that cannot be diversified away. Endonovo Therapeutics holds a performance score of 9 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.0302, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Endonovo Therapeutics are expected to decrease at a much lower rate. During the bear market, Endonovo Therapeutics is likely to outperform the market. Use Endonovo Therapeutics information ratio, as well as the relationship between the daily balance of power and relative strength index , to analyze future returns on Endonovo Therapeutics.
Auto-correlation | 0.00 |
No correlation between past and present
Endonovo Therapeutics has no correlation between past and present. Overlapping area represents the amount of predictability between Endonovo Therapeutics time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Endonovo Therapeutics price movement. The serial correlation of 0.0 indicates that just 0.0% of current Endonovo Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 0.13 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Endonovo Therapeutics reported net income of (3.1 Million). This is 100.91% lower than that of the Biotechnology sector and 104.43% lower than that of the Health Care industry. The net income for all United States stocks is 100.54% higher than that of the company.
Endonovo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Endonovo Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Endonovo Therapeutics could also be used in its relative valuation, which is a method of valuing Endonovo Therapeutics by comparing valuation metrics of similar companies.Endonovo Therapeutics is currently under evaluation in net income category among its peers.
Endonovo Fundamentals
| Return On Asset | -1.1 | |||
| Operating Margin | (222.06) % | |||
| Current Valuation | 9.74 M | |||
| Shares Outstanding | 194.33 M | |||
| Shares Owned By Insiders | 24.61 % | |||
| Price To Earning | (1.04) X | |||
| Price To Sales | 202.42 X | |||
| Revenue | 73.11 K | |||
| Gross Profit | 58.12 K | |||
| EBITDA | (1.51 M) | |||
| Net Income | (3.1 M) | |||
| Cash And Equivalents | 59.98 K | |||
| Total Debt | 7.36 M | |||
| Book Value Per Share | (0.12) X | |||
| Cash Flow From Operations | (986.58 K) | |||
| Earnings Per Share | (0.04) X | |||
| Beta | 0.49 | |||
| Market Capitalization | 3.4 M | |||
| Total Asset | 2.01 M | |||
| Retained Earnings | (17.63 M) | |||
| Working Capital | (8.04 M) | |||
| Current Asset | 245 K | |||
| Current Liabilities | 8.29 M | |||
| Z Score | -16.0 | |||
| Net Asset | 2.01 M |
About Endonovo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Endonovo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Endonovo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Endonovo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Endonovo Pink Sheet Analysis
When running Endonovo Therapeutics' price analysis, check to measure Endonovo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Endonovo Therapeutics is operating at the current time. Most of Endonovo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Endonovo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Endonovo Therapeutics' price. Additionally, you may evaluate how the addition of Endonovo Therapeutics to your portfolios can decrease your overall portfolio volatility.